Effects of CD34(+) selected stem cells for the treatment of poor graft function after allogeneic stem cell transplantation.
10.3760/cma.j.issn.0253-2727.2018.10.008
- Author:
Xin Hong FEI
1
;
Jun Bao HE
;
Hao Yu CHENG
;
Yu Ming YIN
;
Wei Jie ZHANG
;
Shu Qin ZHANG
;
Xiao Can WANG
;
Jing Bo WANG
Author Information
1. Aerospace Center Hospital of Peking University, Beijing 100049, China.
- Publication Type:Journal Article
- Keywords:
Allogeneic stem cell transplants;
CD34(+)-selected stem cell;
Graft-versus-host disease;
Poor graft function
- MeSH:
Antigens, CD34;
Graft Survival;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Retrospective Studies;
Transplantation, Homologous
- From:
Chinese Journal of Hematology
2018;39(10):828-832
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and safety of purified CD34(+) stem cell boost in the treatment of poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation (HSCT) . Methods: 12 patients with poor graft function, reported in our hospital during January 2014 to March 2018, were retrospectively analyzed; The donors of 12 patients were HLA mismatched family members, and all treated with donor purified CD34(+) stem cell after G-CSF mobilization, calculating and statistical analyzing the purity of separation and the recovery rate of CD34(+) stem cells. The related complications and the recovery of blood cells after infusion were observed. Results: The purity of CD34(+) cells in the separation products was 92.0% (44.0%-97.0%) , and the recovery rate was 55.0% (45.0%-96.7%) . The median number of CD34(+) cells was 1.9 (0.9-4.4) ×10(6)/kg with CD3(+) cells as 0.6 (0.3-2.0) ×10(4)/kg. The median durations of white blood cells, platelet and red blood cells recoveries were 18 (14-39) , 29 (16-153) and 60 (9-124) days, respectively. All 12 patients didn't experience serious adverse reactions in the process of infusion, 10 patients achieved hematopoietic recovery, 1 case partial remission, 1 case no recovery, without occurrence of aggravated infection, graft versus host disease and other complications. Conclusion: The infusion of donor purified CD34(+) stem cell was a safe and effective method for PGF after allogeneic HSCT.
